Loading...
Loading...
GLMD| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 74.0K |
| Gross Profit | -74.0K |
| Operating Expense | 1,148.0K |
| Operating I/L | -1,222.0K |
| Other Income/Expense | 103.0K |
| Interest Income | 103.0K |
| Pretax | -1,119.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -1,119.0K |
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company specializing in the development of therapeutics for liver diseases. Its primary focus is on the development of Aramchol, an oral therapy currently in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol for HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Additionally, it is developing Amilo-5MER, a 5 amino acid synthetic peptide. Galmed has research and development collaborations and licensing agreements to support the commercialization of its products.
